Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Free Radicals and AntioxidantsNOW IN
    Article

    Supplementation of patients with sickle cell disease with astaxanthin increases plasma- and erythrocyte-astaxanthin and may improve the hemolytic component of the disease

    Begoña Ruiz-Núñez1★, Stéphanie A. De Rooij1, Pieter J. Offringa2, Gert E. Schuitemaker3, Tom Teerlink4, Hose S.M. Booi5, Janneke D.A. Dijck-Brouwer1, Frits A.J. Muskiet1★ Corresponding author

    1. 1University of Groningen, University Medical Center Groningen, Department of Laboratory Medicine, 9700 RB Groningen, The Netherlands.
    2. 2Sint Maarten Medical Center, Department of Pediatrics, Sint Maarten (Dutch Part).
    3. 3Ortho Institute, 7081 CM Gendringen, The Netherlands.
    4. 4VU University Medical Center, Department of Clinical Chemistry, 1081 HV Amsterdam, The Netherlands.
    5. 5Sint Maarten Laboratory Services, Sint Maarten (Dutch Part).

    CORRESPONDENCE

    Begoña Ruiz-Núñez

    University of Groningen, University Medical Center Groningen, Department of Laboratory Medicine, 9700 RB Groningen, The Netherlands.

    b.ruiz-nunez@umcg.nl

    Received: 15-07-2013; Revised: 11-10-2013; Accepted: 11-11-2013.

    Volume 3, Issue 2S · pp. s22–s29 · PUBLISHED · DOI: 10.1016/j.fra.2013.10.003

    View on Free Rad. Antiox. original site ↗

    ABSTRACT

    Aim & background:Sickle cell disease (SCD) is characterized by hemolytic and vaso-occlusive compo- nents. Astaxanthin is a carotenoid of marine origin, without pro-oxidant properties. Methods: In this open label pilot study, we investigated whether orally administered astaxanthin in- corporates into erythrocytes (RBC) of SCD patients and studied the effect on hematological and clinical chemical parameters. Ten SCD patients (6e52 years) in Sint Maarten received 8e12 mg astaxanthin during 3 months. Results: Baseline plasma- (33 nmol/L) and RBC- (11 nmol/L packed RBC) astaxanthin increased to 225, 174, 167 nmol/L (plasma) and 149, 100, 71 nmol/L packed RBC at 1e3 months, respectively. Reticulocytes decreased from baseline and 2 months (9.5 and 8.8%) to 3 months (5.6%), MCV from 2 to 3 months (88 e86 fL), MCH from baseline to 3 months (30e28 pg) and RDW from baseline and 2 months (19.2 and 19.0%) to 3 months (16.7%). Plasma arginine decreased from 2 to 3 months (46.6e39.4 mmol/L). Asym- metric dimethylarginine (ADMA) did not change. Reticulocytes at baseline correlated with relative changes in reticulocytes from baseline to 3 months. Relative changes in reticulocytes correlated with relative changes in RBC, RDW, LDH, ALAT, but not hematocrit, within the same period. Conclusion:Astaxanthin incorporates into SCD RBC and may favorably affect the hemolytic component. A larger randomized controlled trial is indicated, using similar or higher dose, preferably during more than 3 months, concomitant with (other) low dose antioxidants (vitamin E, beta-carotene, vitamin C, folic acid), minerals (zinc, if necessary, selenium), arginine, fish oil and vitamin D.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Ruiz-Núñez, B., Rooij, S. A. D., Offringa, P. J., Schuitemaker, G. E., Teerlink, T., Booi, H. S., Dijck-Brouwer, J. D., & Muskiet, F. A. (). Supplementation of patients with sickle cell disease with astaxanthin increases plasma- and erythrocyte-astaxanthin and may improve the hemolytic component of the disease. Free Radicals and Antioxidants, 3(2S), s22–s29. https://doi.org/10.1016/j.fra.2013.10.003